APEX1 and cholangiocarcinoma: Serum APEX1 level was higher in CCA patients having metastasis than in those having no metastasis (Figure 4B), suggesting that this protein might be used as a potential serum biomarker for discriminating metastatic and non-metastatic CCA patients.